- Home
- / Nurix Therapeutics
Nurix Therapeutics
Revenue
$84 M
FY, 2025
Nurix Therapeutics Summary
Company Summary
- Overview
- Nurix Therapeutics is a clinical-stage biopharmaceutical company. It specializes in the discovery, development, and commercialization of protein degradation medicines for patients with cancer and inflammatory diseases.
- Type
- Public
- Status
- Active
- Founded
- 2012
- HQ
- San Francisco, CA, US | view all locations
- Website
- https://www.nurixtx.com
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Hans van Houte, Chief Financial Officer
Gwenn M. Hansen, Chief Scientific Officer
Lori A. Kunkel, Director
LocationsView all
1 location detected
San Francisco, CA HQ
United States
1700 Owens Street, Suite 205
Nurix Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $6.3M
- Net income (Q1, 2026)
- ($87.2M)
- Cash (Q1, 2026)
- $71.2M
- EBIT (Q1, 2026)
- ($92.5M)